Improved glycemic control induced by both metformin and repaglinide is associated with a reduction in blood levels of 3-deoxyglucosone in nonobese patients with type 2 diabetes

Research output: Contribution to journalJournal articleResearchpeer-review

Lian Engelen, Søren S Lund, Isabel Ferreira, Lise Tarnow, Hans-Henrik Parving, Jørgen Gram, Kaj Flemming Winther Hansen, Oluf Pedersen, Tom Teerlink, Rob Barto, Coen D A Stehouwer, Allan A Vaag, Casper G Schalkwijk

Metformin has been reported to reduce a-dicarbonyls, which are known to contribute to diabetic complications. It is unclear whether this is due to direct quenching of a-dicarbonyls or to an improvement in glycemic control. We therefore compared the effects of metformin versus repaglinide, an antihyperglycemic agent with an insulin-secreting mechanism, on the levels of the a-dicarbonyl 3-deoxyglucosone (3DG).
Original languageEnglish
JournalEuropean Journal of Endocrinology
Issue number3
Pages (from-to)371-9
Number of pages9
Publication statusPublished - 2011

    Research areas

  • Carbamates, Confidence Intervals, Deoxyglucose, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Metformin, Piperidines

ID: 35312496